📢 We have interesting insights into German market access.

 

Within the Access Briefing Q4 2025, Ecker + Ecker delivers exciting decisions and developments from the German HTA landscape. Read a brief summary 👇️

 

 The highlights:

🏛️ One assessment of a known active subtance with new market exclusivity due to hybrid application

📝 One assessment of a known active substance with new data protection

📋 One assessment of a last-resort antibiotic

🔍 One Reassessment due to loss of orphan drug status

🧬 Six orphan drug reassessments after exceeding 30 Mio €

⏰ Two Reassessments after expiry of deadline

💊 Implementation of the appropriate comparator "individual therapy" due to slicing in four assessments

 

The stats:

🌟 Major additional benefit: 2 (6%)

👌 Considerable additional benefit: 1 (3%)

👍 Minor additional benefit: 6 (17%)

✅ Benefit considered proven: 1 (3%)

⭕️ Non-quantifiable additional benefit: 3 (9%)

❌ No additional benefit: 21 (62%)

 

📝 Register here to receive the latest and upcoming issues of the complete Access Briefing with HTA insights from 13 countries, compiled by 8 partners of our network.